Interactions between the immune system and cancer: A brief review of non-spatial mathematical models

Bulletin of Mathematical Biology

Volumn 73, Issue 1, 2011, Pages 2-32

  Eftimie, Raluca ^a   Bramson, Jonathan L ^b,c   Earn, David J D ^a,c  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

Cancer; Immunology; Ordinary differential equations (ODEs); Tumor immune system interaction

Indexed keywords

EID: 79151470316     PISSN: 00928240     EISSN: 15229602     Source Type: Journal    
DOI: 10.1007/s11538-010-9526-3     Document Type: Review

References (125)

1. Adam, J., Bellomo, N., 1997. A Survey of Models for Tumor-Immune System Dynamics. Birkhäuser, Basel.
2. Alarcon, T., Byrne, H., Maini, P., 2003. A cellular automaton model for tumor growth in inhomogeneous environment. J. Theor. Biol. 225, 257-274.
3. Araujo, R., McElwain, D., 2004. A history of the study of solid tumor growth: the contribution of mathematical modeling. Bull. Math. Biol. 66, 1039-1091.
4. Arciero, J., Jackson, T., Kirschner, D., 2004. A mathematical model of tumor-immune evasion and siRNA treatment. Discrete Contin. Dyn. Syst., Ser. B 4(1), 39-58.
5. Bajzer, Z., Maruĉić, M., Vuk-Pavlović, S., 1996. Conceptual frameworks for mathematical modeling of tumor growth dynamics. Math. Comput. Model. 23(6), 31-46.
6. Banerjee, S., Sarkar, R., 2008. Delay-induced model for tumor-immune interaction and control of malignant tumor growth. BioSystems 91, 268-288.
7. Bellomo, N., Delitala, M., 2008. From the mathematical kinetic, and stochastic game theory to modeling mutations, onset, progression and immune competition of cancer cells. Phys. Life Rev. 5, 183-206.
8. Bellomo, N., Preziosi, L., 2000. Modelling and mathematical problems related to tumor evolution and its interactions with the immune system. Math. Comput. Model. 32, 413-452.
9. Bellomo, N., Li, N., Maini, P., 2008. On the foundations of cancer modeling: selected topics, speculations, and perspectives. Math. Mod. Methods Appl. Sci. 18(4), 593-646.
10. + T cell help. J. Exp. Med. 186(1), 65-70.
11. + T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy. Nat. Med. 13, 354-360.
12. Boon, T., van der Bruggen, P., 1996. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183, 725-729.
13. Bose, T., Trimper, S., 2009. Stochastic model for tumor growth with immunization. Phys. Rev. E 79, 5.
14. Bunimovich-Mendrazitsky, S., Shochat, E., Stone, L., 2007. Mathematical model of BCG immunotherapy in superficial bladder cancer. Bull. Math. Biol. 69, 1847-1870.
15. Burger, P., Vogel, F., Green, S., Strike, T., 1985. Glioblastoma multiforme and anaplastic astrocytoma, pathologic criteria and prognosis implications. Cancer 56, 1106-1111.
16. Burnet, F., 1957. Cancer: a biological approach. Br. Med. J. 1, 779-786.
17. Burnet, F., 1967. Immunological aspects of malignant disease. Lancet 1, 1171-1174.
18. Byrne, H., Cox, S., Kelly, C., 2004. Macrophage-tumor interactions: in vivo dynamics. Discrete Contin. Dyn. Syst., Ser. B 4(1), 81-98.
19. Byrne, H., Alarcon, T., Owen, M., Webb, S., Maini, P., 2006. Modeling aspects of cancer dynamics: a review. Philos. Trans. R. Soc. A 364, 1563-1578.
20. Cappuccio, A., Elishmereni, M., Agur, Z., 2006. Cancer immunotherapy by Interleukin-21: potential treatment strategies evaluated in a mathematical model. Cancer Res. 66(14), 7293-7300.
21. Castiglione, F., Piccoli, B., 2007. Cancer immunotherapy, mathematical modeling and optimal control. J. Theor. Biol. 247, 723-732.
22. Castro, M., Klamt, F., Grieneisen, V., Grivicich, I., Moreira, J., 2003. Gompertzian growth pattern correlated with phenotypic organization of colon carcinoma, malignant glioma and non-small cell lung carcinoma cell lines. Cell Proliferation 36, 65-73.
23. Chaplain, M., 2008. Modelling aspects of cancer growth: insight from mathematical and numerical analysis and computational simulation. In: Multiscale Problems in the Life Sciences. Lecture Notes in Mathematics, vol. 1940, pp. 147-200. Springer, Berlin.
24. Chatterjee, A., Mayawala, K., Edwards, J., Vlachos, D., 2005. Time accelerated Monte Carlo simulations of biological networks using the binomial τ-leap method. Bioinformatics 21(9), 2136-2137.
25. Chignola, R., Foroni, R., 2005. Estimating the growth kinetics of experimental tumors from as few as two determinations of tumor size: implications for clinical oncology. IEEE Trans. Biomed. Eng. 52(5), 808-815.
26. de Boer, R., Hogeweg, P., Dullens, H., de Weger, R., den Otter, W., 1985. Macrophage T lymphocyte interactions in the anti-tumor immune response: a mathematical model. J. Immunol. 134(4), 2748-2758.
27. de Pillis, L., Radunskaya, A., 2001. A mathematical tumor model with immune resistance and drug therapy: an optimal control approach. Comput. Math. Methods Med. 3(2), 78-100.
28. de Pillis, L., Radunskaya, A., 2003a. The dynamics of an optimally controlled tumor model: a case study. Math. Comput. Model. 37, 1221-1244.
29. de Pillis, L., Radunskaya, A., 2003b. A mathematical model of immune response to tumor invasion. In: Computational Fluid and Solid Mechanics. Proceedings of the Second M. I. T. Conference on Computational Fluid Dynamics and Solid Mechanics, pp. 1661-1668.
30. de Pillis, L., Radunskaya, A., Wiseman, C., 2005. A validated mathematical model of cell-mediated immune response to tumor growth. Cancer Res. 65(17), 7950-7958.
31. de Vladar, H., González, J., 2004. Dynamic response of cancer under the influence of immunological activity and therapy. J. Theor. Biol. 227, 335-348.
32. di Carlo, E., de Totero, D., Piazza, T., Fabbi, M., Ferrini, S., 2007. Role of IL-21 in immune-regulation and tumor immunotherapy. Cancer Immunol. Immunother. 56, 1323-1334.
33. Diefenbach, A., Jensen, E., Jamieson, A., Raulet, D., 2001. Rael and H60 ligands of the NKG2D receptor stimulate tumor immunity. Nature 413, 165-171.
34. d'Onofrio, A., 2005. A general framework for modeling tumor-immune system competition and immunotherapy: mathematical analysis and biomedical inferences. Physica D 208, 220-235.
35. d'Onofrio, A., 2008. Metamodeling tumor-immune system interaction, tumor evasion and immunotherapy. Math. Comput. Model. 47, 614-637.
36. Dranoff, G., 2004. Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer 4, 11-22.
37. Dullens, H., Tol, M. V. D., de Weger, R., Otter, W. D., 1986. A survey of some formal models in tumor immunology. Cancer Immunol. Immunother. 23, 159-164.
38. Fidler, I., 1985. Macrophages and metastasis: a biological approach to cancer therapy: presidential address. Cancer Res. 45, 4714-4726.
39. Forys, U., Waniewski, J., Zhivkov, P., 2006. Anti-tumor immunity and tumor anti-immunity in a mathematical model of tumor immunotherapy. J. Biol. Syst. 14(1), 13-30.
40. Gajewski, T., 2007. Failure at the effector phase: immune barriers at the level of melanoma tumor microenvironment. Clin. Cancer Res. 13(18), 5256-5261.
41. Galach, M., 2003. Dynamics of the tumor-immune system competition: the effect of time delay. Int. J. Appl. Math. Comput. Sci. 13(3), 395-406.
42. Gerlee, P., Anderson, A., 2009. Evolution of cell motility in an individual-based model of tumor growth. J. Theor. Biol. 259(1), 67-83.
43. Gillespie, D., 1976. A general method for numerically simulating the stochastic time evolution of coupled chemical reactions. J. Comput. Phys. 22(4), 403-434.
44. Goldstein, B., Faeder, J., Hlavacek, W., 2004. Mathematical and computational models of immune-receptor signaling. Nat. Rev. Immunol. 4(6), 445-456.
45. Gompertz, B., 1825. On the nature of the function expressive of the law of human mortality, and on a new mode of determining the value of life contingencies. Philos. Trans. R. Soc. Lond. 115, 513-583.
46. Greenblatt, M., Bennett, W., Hollstein, M., Harris, C., 1994. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54, 4855-4878.
47. Hamilton, D., Bretscher, P., 2008. The commonality in the regulation of the immune response to most tumors: the prevalence of immune class deviation as a tumor escape mechanism and its significance for vaccination and immunotherapy. Cancer Ther. 6, 745-754.
48. Hart, D., Shochat, E., Agur, Z., 1998. The growth law of primary breast cancer as inferred from mammography screening trials data. Br. J. Cancer 78, 382-387.
49. Horny, H.-P., Horst, H.-A., 1986. Lymphoreticular infiltrates in invasive ductal breast cancer. Virchows Arch. 409, 275-286.
50. Kammertoens, T., Schüler, T., Blankenstein, T., 2005. Immunotherapy: target the stroma to hit the tumor. Trends Mol. Med. 11(5), 225-231.
51. Khar, A., 1997. Mechanisms involved in natural killer cell mediated target cell death leading to spontaneous tumor regression. J. Biosci. 22, 23-31.
52. Kim-Schulze, S., Taback, B., Kaufman, H., 2007. Cytokine therapy for cancer. Surg. Oncol. Clin. N. Am. 16(4), 793-818.
53. Kirk, D., 2004. Optimal Control Theory: An Introduction. Dover, New York.
54. Kirschner, D., Panetta, J., 1998. Modeling immunotherapy of the tumor-immune interaction. J. Math. Biol. 37, 235-252.
55. Knudson, A., 1971. Mutations and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. 68(4), 820-823.
56. Kronik, N., Kogan, Y., Vainstein, V., Agur, Z., 2008. Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics. Cancer Immunol. Immunother. 57, 425-439.
57. Kruse, C., Cepeda, L., Owens, B., Johnson, S., Stears, J., Lillehei, K., 1997. Treatment of recurrent glioma with intracavity alloreactive cytotoxic T lymphocytes and Interleukin-2. Cancer Immunol. Immunother. 45, 77-87.
58. Kurtz, T., 1971. Limit theorems for sequences of jump Markov processes approximating ordinary differential processes. J. Appl. Probab. 8(2), 344-356.
59. Kuznetsov, Y., 1994. Elements of Applied Bifurcation Theory. Springer, London.
60. Kuznetsov, V., Makalkin, I., Taylor, M., Perelson, A., 1994. Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis. Bull. Math. Biol. 2(56), 295-321.
61. Laird, A., 1964. Dynamics of tumor growth. Br. J. Cancer 18, 490-502.
62. Lala, P., Patt, H., 1966. Cytokinetic analysis of tumor growth. Proc. Natl. Acad. Sci. 56, 1735-1742.
63. Ledzewicz, U., Munden, J., Schättler, H., 2009. Scheduling of angiogenic inhibitors for Gompertzian and logistic tumor growth models. Discrete Contin. Dyn. Syst. Ser. B 12(2), 415-438.
64. Leek, R., Harris, A., 2002. Tumor-associated macrophages in breast cancer. J. Mammary Gland Biol. Neoplasi 7(2), 177-189.
65. Lejeune, O., Chaplain, M., Akili, I. E., 2008. Oscillations and bistability in the dynamics of cytotoxic reactions mediated by the response of immune cells to solid tumors. Math. Comput. Model. 47, 649-662.
66. Lin, A., 2004. A model of tumor and lymphocyte interactions. Discrete Contin. Dyn. Syst. Ser. B 4(1), 241-266.
67. Lollini, P., Motta, S., Pappalardo, F., 2006a. Discovery of cancer vaccination protocols with a genetic algorithm driving and agent based simulator. BMC Bioinform. 7, 352.
68. Lollini, P., Motta, S., Pappalardo, F., 2006b. Modeling tumor immunology. Math. Mod. Methods Appl. Sci. 16(7S), 1091-1124.
69. Malet, D., de Pillis, L., 2006. A cellular automata model of tumor-immune system interactions. J. Theor. Biol. 239, 334-350.
70. Mansury, Y., Diesboeck, T., 2003. The impact of "search precision" in an agent-based tumor model. J. Theor. Biol. 224, 325-337.
71. Mansury, Y., Diggory, M., Deisboeck, T., 2006. Evolutionary game theory in an agent-based brain tumor model: exploring the 'Genotype-Phenotype' link. J. Theor. Biol. 238, 146-156.
72. Mantovani, A., Sozzani, S., Locati, M., Allavena, P., Sica, A., 2002. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. TRENDS Immunol. 23(11), 549-555.
73. Martins, M., Ferreira, S. C. Jr., Vilela, M., 2007. Multiscale models for the growth of avascular tumors. Phys. Life Rev. 4, 128-156.
74. Matkowski, B., 1970. Nonlinear dynamics stability. SIAM J. Appl. Math. 18, 872-883.
75. Mattes, J., Hulett, M., Xie, W., Hogan, S., Rothenberg, M., Foster, P., Parish, C., 2003. Immunotherapy of cytotoxic T cell-resistant tumor by T helper 2 cells: an eotaxin and STAT6-dependent process. J. Exp. Med. 197(3), 387-393.
76. Matzavinos, A., Chaplain, M., Kuznetsov, V., 2004. Mathematical modeling of the spatiotemporal response of cytotoxic T-lymphocytes to a solid tumour. Math. Med. Biol. 21(1), 1-34.
77. Menta, B., Agarwal, M., 1980. Cyclic oscillations in leukocyte count in chronic myeloid leukemia. Acta Haematol. 63, 68-70.
78. Merola, A., Cosentino, C., Amato, F., 2008. An insight into tumor dormancy equilibrium via the analysis of its domain of attraction. Biomed. Sign. Process. Control 3, 212-219.
79. Michelson, S., Leith, J., 1993. Growth factors and growth control of heterogeneous populations. Bull. Math. Biol. 55, 993-1011.
80. Michelson, S., Miller, B., Glicksman, A., Leith, J., 1987. Tumor micro-ecology and competitive interactions. J. Theor. Biol. 128, 233-246.
81. Moore, H., Li, N., 2004. A mathematical model for chronic myelogenous leukemia (CML) and T cell interaction. J. Theor. Biol. 227, 513-523.
82. Mueller, M., Fusenig, N., 2004. Friends or foes-bipolar effects of the tumor stroma in cancer. Nat. Rev. 4, 839-849.
83. Nagy, J., 2005. The ecology and evolutionary biology of cancer: a review of mathematical models of necrosis and tumor cells diversity. Math. Biosci. Eng. 2(2), 381-418.
84. + T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cells. Cancer Res. 58, 3491-3494.
85. Nani, F., Freedman, H., 2000. A mathematical model of cancer treatment by immunotherapy. Math. Biosci. 163, 159-199.
86. Norton, L., 1988. A Gompertzian model of human breast cancer growth. Cancer Res. 48, 7067-7071.
87. Nowak, M., Komarova, N., Sengupta, A., Jallepalli, P., Shih, I., Vogelstein, B., Lengauer, C., 2002. The role of chromosomal instability in tumor initiation. Proc. Natl. Acad. Sci. 99(25), 16226-16231.
88. Orucevic, A., Lala, P., 1998. Role of nitric oxide in IL-2 therapy-induced capillary leak syndrome. Cancer Metastasis Rev. 17(1), 127-142.
89. Owen, M., Sherratt, J., 1998. Modeling the macrophage invasion of tumors: effects on growth and composition. Math. Med. Biol. 15, 165-185.
90. Owen, M., Byrne, H., Lewis, C., 2004. Mathematical modeling of the use of macrophages as vehicles for drug delivery to hypoxic tumor sites. J. Theor. Biol. 226, 377-391.
91. Page, K., Uhr, J., 2005. Mathematical models of cancer dormancy. Leuk. Lymphoma 46, 313-327.
92. Panetta, J., 1998. A mathematical model of drug resistance: heterogeneous tumors. Math. Biosci. 147, 41-61.
93. Pappalardo, F., Lollini, P.-L., Castiglione, F., Motta, S., 2005. Modelling and simulation of cancer immunoprevention vaccine. Bioinformatics 21, 2891.
94. Pappalardo, F., Motta, S., Lollini, P.-L., Mastriani, E., 2006. Analysis of vaccine's schedule using models. Cell. Immunol. 244, 137-140.
95. Parish, C., 2003. Cancer immunotherapy: the past, the present and the future. Immunol. Cell Biol. 81, 106-113.
96. Parmiani, G., Rivoltini, L., Andreola, G., Carrabba, M., 2000. Cytokines in cancer therapy. Immunol. Lett. 74(1), 41-44.
97. Perez-Diez, A., Joncker, N., Choi, K., Chan, W., Anderson, C., Lantz, O., Matzinger, P., 2007. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 109, 5346-5354.
98. Perko, L., 2001. Differential Equations and Dynamical Systems. Springer, Berlin.
99. Quesnel, B., 2008. Dormant tumor cells as therapeutic target? Cancer Lett. 267, 10-17.
100. Roose, T., Chapman, S., Maini, P., 2007. Mathematical models of avascular tumor growth. SIAM Rev. 49(2), 179-208.
101. Rosenberg, S., 1991. Immunotherapy and gene therapy of cancer. Cancer Res. 51, 5074s-5079s.
102. Rosenberg, S., Yang, J., Restifo, N., 2004. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10, 909-915.
103. Sachs, R., Hlatky, L., Hahnfeldt, P., 2001. Simple ODE models of tumor growth and anti-angiogenic or radiation treatment. Math. Comput. Model. 33, 1297-1305.
104. Samad, H. E., Khammash, M., Petzold, L., Gillespie, D., 2005. Stochastic modeling of gene regulatory networks. Int. J. Robust Nonlinear Control 15, 691-711.
105. Sarkar, R., Banerjee, S., 2005. Cancer self remission and tumor stability-a stochastic approach. Math. Biosci. 196, 65-81.
106. Skipper, H., Schabel, F. H. Jr., 1982. Quantitative and cytokinetic studies in experimental tumor systems. In: Holland, J., Frey E. III (Eds.), Cancer Medicine, 2nd edn., pp. 636-648.
107. Smyth, M., Godfrey, D., Trapani, J., 2001. A fresh look at tumor immunosurveillance and immunotherapy. Nat. Immunol. 2, 293-299.
108. Sotolongo-Costa, O., Molina, L. M., Perez, D. R., Antoraz, J., Reyes, M. C., 2003. Behavior of tumors under nonstationary therapy. Physica D 178, 242-253.
109. Spratt, J., Meyer, J., Spratt, J., 1996. Rates of growth of human neoplasms: part ii. J. Surg. Oncol. 61, 68-83.
110. Stepanova, N., 1980. Course of the immune reaction during the development of a malignant tumor. Biophysics 24, 917-923.
111. Stuart, J., 1960. On the nonlinear mechanism of wave disturbances in stable and unsable parallel flows. Part I. J. Fluid Mech. 9, 353-370.
112. Swan, G., 1985. Optimal control applications in the chemotherapy of multiple myeloma. IMA J. Math. Appl. Med. Biol. 2(3), 139-160.
113. Szymanska, Z., 2003. Analysis of immunotherapy models in the context of cancer dynamics. Int. J. Appl. Math. Comput. Sci. 13, 407-418.
114. Takayanagi, T., Ohuchi, A., 2001. A mathematical analysis of the interactions between immunogenic tumor cells and cytotoxic T lymphocytes. Microbiol. Immunol. 45(10), 709-715.
115. Teng, M., Swann, J., Koebel, C., Schreiber, R., Smyth, M., 2008. Immune-mediated dormancy: an equilibrium with cancer. J. Leukoc. Biol. 84, 988-993.
116. Thorne, B., Bailey, A., Peirce, S., 2007. Combining experiments with multi-cell agent-based modeling to study biological tissue patterning. Brief. Bioinform. 8(4), 245-257.
117. Villasana, M., Radunskaya, A., 2003. A delay differential equation model for tumor growth. J. Math. Biol. 47, 270-294.
118. von Bertalanffy, L., 1957. Quantitative laws in metabolism and growth. Q. Rev. Biol. 32, 217-231.
119. von Stebut, E., Metz, M., Milon, G., Knop, J., Maurer, M., 2003. Early macrophage influx to sites of cutaneous granuloma formation is dependent on MIP-1α/β released from neutrophils recruited by mast cell-derived TNF-α. Blood 101, 210-215.
120. Waldhauer, I., Steinle, A., 2008. NK cells and cancer immunosurveillance. Oncogene 27, 5932-5943.
121. Wang, S., Hinow, P., Bryce, N., Weaver, A., Estrada, L., Artega, C., Webb, G., 2009. A mathematical model quantifies proliferation and motility effects of TGF-β on cancer cells. Comput. Math. Methods Med. 10(1), 71-83.
122. Webb, S., Owen, M., Byrne, H. M., Murdoch, C., Lewis, C., 2007. Macrophage-based anti-cancer therapy: modeling different modes of tumour targeting. Bull. Math. Biol. 69(5), 1747-1776.
123. Weedon-Fekjaer, H., Lindqvist, B., Vatten, L., Aalen, O., Tretli, S., 2008. Breast cancer tumor growth estimated through mammography screening data. Breast Cancer Res. 10, R41.
124. Weldon, T., 1988. Mathematical Models in Cancer Research. Hilger, Bristol.
125. + T-cell-mediated anti-tumor immunity can be uncoupled from autoimmunity via the STAT4/STAT6 signaling axis. Eur. J. Immunol. 39, 1252-1259.